Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder

Yiğit Kaya, SüreyyaAşkın, Abdullah EmreBektaş, ŞebnemÇakır, AslıGökmen Sevindik, Ömür2023-05-242023-05-242023Yiğit Kaya, S., Aşkın, A. E., Bektaş, Ş., Çakır, A. ve Gökmen Sevindik, Ö. (2023). Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder. Leukemia Research Reports, 19. https://doi.org/10.1016/j.lrr.2023.1003692213-0489https://doi.org/10.1016/j.lrr.2023.100369https://hdl.handle.net/20.500.12511/10965Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessAcute Myeloid Leukemia (AML)Epstein-Barr VirusPost Transplant Lymphoproliferative DisorderRituximabNewly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorderArticle1910.1016/j.lrr.2023.100369N/A0010516400000012-s2.0-8515614467237213444Q3